AGP Executive Report
Last update: 5 hours agoSleep Research: A major review found too little reliable evidence to show medical cannabis improves insomnia, sleep duration or daytime functioning. Safety Standards: The American Medical Association urged the FDA to apply rigorous drug-safety and efficacy standards to cannabis and other botanical products, including clinical trials and post-market monitoring. Global Policy: Nepal’s Supreme Court has ordered the government to create rules for controlled cannabis cultivation for medicinal, scientific, agricultural and industrial use. Patient Access: A UK epilepsy patient who found seizure relief with medical cannabis still cannot get it through the NHS; the Dutch producer of his oil, Bedrolite, has gone bankrupt, putting future supply at risk. US Regulation: The DEA has begun registering more than 900 medical cannabis dispensaries and warned businesses to source products only from federally registered companies. A federal ban on synthetic hemp cannabinoids is also set to take effect Nov. 12.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
